Home > Journals > International Angiology > Past Issues > International Angiology 2018 February;37(1) > International Angiology 2018 February;37(1):59-63

CURRENT ISSUE
 

ARTICLE TOOLS

Publication history
Reprints
Cite this article as

INTERNATIONAL ANGIOLOGY

A Journal on Angiology


Official Journal of the International Union of Angiology, the International Union of Phlebology and the Central European Vascular Forum
Indexed/Abstracted in: BIOSIS Previews, Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,37


eTOC

 

ORIGINAL ARTICLE  


International Angiology 2018 February;37(1):59-63

DOI: 10.23736/S0392-9590.17.03886-X

Copyright © 2017 EDIZIONI MINERVA MEDICA

language: English

Drug-coated balloons reduce the risk of recurrent restenosis in arteriovenous fistulas and prosthetic grafts for hemodialysis

Nicola TROISI 1 , Pierfrancesco FROSINI 1, Chiara SOMMA 2, Eugenio ROMANO 1, Azzurra GUIDOTTI 1, Pietro C. DATTOLO 2, Giuseppe FERRO 2, Emiliano CHISCI 1, Stefano MICHELAGNOLI 1

1 Department of Surgery, Unit of Vascular and Endovascular Surgery, San Giovanni di Dio Hospital, Florence, Italy; 2 Department of Medicine, Unit of Nephrology and Dialysis, Santa Maria Annunziata Hospital, Bagno a Ripoli, Florence, Italy


PDF  


BACKGROUND: Aim of this study was to evaluate the early and mid-term outcomes of drug-coated balloons (DCBs) in hemodialysis patients with recurrent stenosis of arteriovenous fistula and previously treated with plain balloon angioplasty (PBA).
METHODS: Between July 2013 and June 2016 38 hemodialysis patients with recurrent stenosis of arteriovenous fistula underwent endovascular treatment with a DCB at our center. All patients were previously treated at the target lesion with a PBA. The intervals in months between the standard PBA and the procedure with DCB (time PBA-DCB) and between the procedure with DCB and the restenosis at the target lesion (time DCB-restenosis) were evaluated and compared with T-test. Estimated outcomes at 2 years in terms of patient survival, primary patency, primary assisted patency, secondary patency, and freedom from target lesion restenosis were assessed with Kaplan-Meier curves.
RESULTS: Intraprocedural technical success was obtained in 97.4% of the cases. During the follow-up (mean duration 14.3 months, range 2-33) 19 patients (50%) developed a restenotic lesion at the target lesion with an estimated 2-year freedom from target lesion restenosis of 32.8%. Mean time PBA-DCB was 6.4 months, and the mean time DCB-restenosis was 7.9 months with a statistically significant difference at T-test (P<0.001). Estimated 2-year rates of primary patency, primary assisted patency, and secondary patency were 40.8%, 73.1%, and 82.5%, respectively.
CONCLUSIONS: In our experience DCBs were safe and effective in the treatment of recurrent stenosis in patients with failing arteriovenous fistula. The time to restenosis at the target lesion was longer respect to that necessary to have a recurrent restenosis after PBA.


KEY WORDS: Arteriovenous fistula - Renal dialysis - Treatment outcome

top of page

Publication History

Issue published online: January 2, 2018
Article first published online: November 10, 2017
Manuscript accepted: November 7, 2017
Manuscript revised: November 4, 2017
Manuscript received: July 14, 2017

Cite this article as

Troisi N, Frosini P, Somma C, Romano E, Guidotti A, Dattolo PC, et al. Drug-coated balloons reduce the risk of recurrent restenosis in arteriovenous fistulas and prosthetic grafts for hemodialysis. Int Angiol 2018;37:59-63. DOI: 10.23736/S0392-9590.17.03886-X

Corresponding author e-mail

troisimd@gmail.com